New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options ...
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET ...
Rusfertide (Mimrylo) significantly improved hematocrit control and reduced the need for therapeutic phlebotomy in patients ...
Vojnic is director of neuro-oncology at Rutgers Cancer Institute and system leader for neuro-oncology at RWJBarnabas Health.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
Swiecicki, MD, of the University of Michigan Rogel Cancer Center, characterizes the safety and tolerability of subcutaneous ...
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has ...
Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...
How to Select First-Line Immunotherapy for Metastatic NSCLC: PD-L1, Disease Burden, and Co-Mutations
Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer. Selecting first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results